^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    RGX-019

    i
    Other names: RGX-019, RGX019, RGX 019
    Company:
    Inspirna, Rockefeller University
    Drug class:
    MERTK-targeted antibody-drug conjugate
    Related drugs:
    12ms
    Targeting Myeloid Epithelial Tyrosine Kinase (MERTK) Receptor in Acute Myeloid Leukemia Using a Novel Antibody Drug Conjugate, Rgx-019-MMAE (ASH 2023)
    Finally, we investigated the synergistic effect of RGX-019-MMAE with Venetoclax (BCL2 inhibitor) or 5-Azacytidine in vitro. RGX-019-MMAE significantly induced cell death in AML cell lines and primary AML patient samples. RGX-019-MMAE, combined with chemotherapeutic agents and targeted therapy, produces a synergistic anti-leukemic effect. Our data indicates that MERTK is a potential therapeutic target in AML patients with monocytic subtypes of leukemia.
    IO biomarker
    |
    AXL (AXL Receptor Tyrosine Kinase) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • MERTK (MER Proto-Oncogene, Tyrosine Kinase)
    |
    PTPN11 mutation • MERTK expression
    |
    Venclexta (venetoclax) • azacitidine • RGX-019 • RGX-019-MMAE
    over4years
    [VIRTUAL] In vivo efficacy and safety of RGX-019, a MerTK targeting monoclonal antibody (AACR-II 2020)
    Additionally, no clinical hematologic toxicities were observed. Pro-inflammatory macrophage-related cytokines were detected in the plasma after RGX-019 dosing, confirming target engagement in vivo.The MOA and safety profile of RGX-019, along with its high selectivity, affinity, in vivo efficacy, and immunologic activity, support further advancement of RGX-019 as a clinical candidate for development in solid and liquid cancers.
    Late-breaking abstract
    |
    AXL (AXL Receptor Tyrosine Kinase) • MERTK (MER Proto-Oncogene, Tyrosine Kinase) • GAS6 (Growth arrest specific 6)
    |
    AXL expression • AXL overexpression • MERTK expression
    |
    RGX-019